A Leading Chipmaker Despite Virus Concerns
Microchip remains our top pick.
Despite concerns about the COVID-19 virus, a potential oil price war, and a recent stock market sell-off, we will maintain our fair value estimates for several wide-moat analog and mixed signal chipmakers across our coverage, such as Microchip Technology ($108 fair value estimate) (MCHP), Texas Instruments ($115) (TXN), Analog Devices ($98) (ADI), and Maxim Integrated ($55) (MXIM). Microchip remains our preferred investment idea in the sector; the stock was a Best Idea in most of 2019 and recently reached our unchanged fair value. However, with shares as low as $78, we think investors have another opportunity to buy this leading wide-moat, broad based chipmaker with an exemplary management team. The other three stocks are equally high quality but only appear to us to be fairly valued after being overvalued as of a couple of weeks ago.
We anticipate that the recent stock market turbulence will become self-fulfilling to chip fundamentals in the near term. Combined with virus headwinds, we suspect that chip customers will likely remain cautious about near-term demand and, in turn, chip orders needed to fulfill their production. Although an industry “bottom” appeared to be formed in late 2019, we fear that an uptick is no longer on the immediate horizon. We have reduced our near-term revenue estimates for Microchip and TI in particular; we now project flattish sales for TI in 2020 and 5% growth in fiscal 2021 (ending March) for Microchip versus the “easy” comparisons of fiscal 2020. Even though chip inventory appears to be at low levels for customers, we’re concerned that these macro issues will also weigh on true end market demand. That said, we also project a stronger snapback in demand after this near-term slowdown, thus negating any drag on our fair value estimate. Longer term, we still believe that the secular trends of rising chip content in automotive, industrial, and "Internet of Things" devices is fully intact.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Brian Colello does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.